Compare FR & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FR | CORT |
|---|---|---|
| Founded | 1993 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4B | 9.7B |
| IPO Year | 1996 | 2001 |
| Metric | FR | CORT |
|---|---|---|
| Price | $62.59 | $117.10 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 5 |
| Target Price | $62.17 | ★ $96.50 |
| AVG Volume (30 Days) | 966.0K | ★ 1.2M |
| Earning Date | 04-22-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.26% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.66 | 0.09 |
| Revenue | $727,076,000.00 | ★ $761,407,000.00 |
| Revenue This Year | $11.27 | $26.08 |
| Revenue Next Year | $7.19 | $26.98 |
| P/E Ratio | ★ $37.87 | $1,271.89 |
| Revenue Growth | 8.58 | ★ 12.79 |
| 52 Week Low | $48.74 | $28.66 |
| 52 Week High | $69.88 | $122.21 |
| Indicator | FR | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 35.24 | 66.55 |
| Support Level | $59.98 | $76.41 |
| Resistance Level | $63.89 | $122.21 |
| Average True Range (ATR) | 1.39 | 5.00 |
| MACD | -0.38 | -0.00 |
| Stochastic Oscillator | 0.69 | 81.48 |
First Industrial Realty Trust Inc is a real estate investment trust that owns, manages, acquires, sells, develops, and redevelops industrial real estate. Through its fully integrated operating and investing platform, the company provides facilities and customer service to multinational corporations and regional firms that are essential for their supply chains. The company serves a diverse tenant base across various sectors, including e-commerce, logistics, transportation, manufacturing, retail, consumer services, food and beverage, building materials, wholesale goods, health services, and government.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.